Takeda’s Mepact Cancer Drug Gets U.K. Health-Cost Agency Backing
This article is for subscribers only.
Takeda Pharmaceutical Co. won the backing of the U.K.’s health-cost agency for its Mepact bone-cancer drug.
Mepact is approved for use with chemotherapy after surgery for bone cancers that haven’t spread, the National Institute for Health and Clinical Excellence said in an e-mailed statement today. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to the statement.